Asset Advisors Corp Maintains Stake in Eli Lilly and Company (NYSE:LLY)

Asset Advisors Corp maintained its position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent filing with the SEC. The firm owned 10,500 shares of the company’s stock at the end of the second quarter. Asset Advisors Corp’s holdings in Eli Lilly and were worth $864,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Joel Isaacson & Co. LLC raised its position in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the last quarter. Washington Trust Bank raised its position in Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the last quarter. Blair William & Co. IL raised its position in Eli Lilly and by 13.1% in the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock valued at $21,974,000 after buying an additional 30,299 shares during the last quarter. Finally, Bollard Group LLC raised its position in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the last quarter. 75.59% of the stock is currently owned by institutional investors and hedge funds.

Shares of Eli Lilly and Company (NYSE LLY) traded down 0.94% during midday trading on Friday, hitting $77.07. The stock had a trading volume of 4,061,282 shares. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The firm has a market cap of $81.31 billion, a price-to-earnings ratio of 33.35 and a beta of 0.34. The company’s 50-day moving average price is $82.39 and its 200-day moving average price is $81.90.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the company earned $0.86 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

ILLEGAL ACTIVITY NOTICE: “Asset Advisors Corp Maintains Stake in Eli Lilly and Company (NYSE:LLY)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/asset-advisors-corp-holds-stake-in-eli-lilly-and-company-nyselly-updated.html.

LLY has been the topic of several research reports. UBS AG lowered Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a research note on Wednesday, July 26th. Argus downgraded Eli Lilly and from a “buy” rating to a “hold” rating and upped their price target for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC restated a “buy” rating and set a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Sanford C. Bernstein reiterated an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and in a report on Sunday, May 21st. Finally, BMO Capital Markets set a $71.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $88.27.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock valued at $55,845,287 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit